Genprex CEO to Interview Live on “The Big Biz Show”
June 24 2020 - 8:16AM
Business Wire
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a
clinical-stage gene therapy company developing potentially
life-changing technologies for patients with cancer and diabetes,
today announced that its Chairman and Chief Executive Officer,
Rodney Varner, will be participating in a live interview with the
“Big Biz Show,” an Emmy Award winning nationally syndicated TV and
radio show, on Thursday, June 25.
The Big Biz Show covers current business events,
internet-related issues and other hot topics in the business world.
The Big Biz Show is seen and heard in over 100 million broadcast TV
homes, 150 radio stations in the U.S. and in 175 countries. The
Emmy Award winning show was named by TALKERS Magazine as one of the
“Top 10 Most Influential Financial Shows.”
The Big Biz Show can be seen and heard every weeknight on YouTOO
America Television Network at 8 p.m. ET, the following morning at 7
a.m. ET, and every weekday on BizTalk Radio at 2 p.m. ET.
Additionally, the show can be accessed digitally by visiting
BizTVClub.com, where you can watch the Big Biz Show every weeknight
at 9 p.m. ET.
During the interview, Mr. Varner will discuss:
- How Genprex is bridging critical gaps in modern medicine by
providing new treatment options to patients with cancer and
diabetes
- The Company’s oncology program and its modern combinational
treatment approach to fight cancer
- The Company’s U.S. FDA Fast Track Designation
- How its diabetes program could eliminate the need for insulin
in diabetic patients
Following the interview, a video recording of Mr. Varner’s
appearance on the Big Biz Show will be made available on Genprex’s
website.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with
cancer and diabetes. Genprex’s technologies are designed to
administer disease-fighting genes to provide new treatment options
for large patient populations with cancer and diabetes who
currently have limited treatment options. Genprex works with
world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies
in order to provide novel treatment approaches. The Company’s lead
product candidate, Oncoprex™, is being evaluated as a treatment for
non-small cell lung cancer (NSCLC). Oncoprex has a multimodal
mechanism of action that has been shown to interrupt cell signaling
pathways that cause replication and proliferation of cancer cells;
re-establish pathways for apoptosis, or programmed cell death, in
cancer cells; and modulate the immune response against cancer
cells. Oncoprex has also been shown to block mechanisms that create
drug resistance. In January 2020, the U.S. Food and Drug
Administration granted Fast Track Designation for Oncoprex
immunogene therapy for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR
mutations whose tumors progressed after treatment with osimertinib
alone. For more information, please visit the Company’s web site at
www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of Oncoprex™, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including our gene therapy in
diabetes, advance into clinical trials; the success of our
strategic partnerships, including those relating to manufacturing
of our products; the timing and success of obtaining FDA approval
of Oncoprex™ and our other potential product candidates including
whether we receive fast track or similar regulatory designations;
costs associated with developing our product candidates and whether
patents will ever be issued under patent applications that are the
subject of our license agreements. These and other risks and
uncertainties are described more fully under the caption “Risk
Factors” and elsewhere in our filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. We undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200624005089/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024